Table 4 Association of HDAC2 expression with various clinicopathological factors
Characteristic | All cases | HDAC 2 low (IRS 0–4) | HDAC 2 intermediate (IRS 6–8) | HDAC 2 high (IRS 9–12) | P-valueχ 2-test for trends |
|---|---|---|---|---|---|
All cases | 212 (100%) | 92 (43.4%) | 69 (32.5%) | 51 (24.1%) | -- |
Histological type | 0.59 | ||||
Ductal carcinoma/Other | 180 (100%) | 80 (44.4%) | 56 (31.1%) | 44 (24.5%) | |
Lobular carcinoma | 27 (100%) | 10 (37%) | 10 (37%) | 7 (26%) | |
Histological grade | <0.001* | ||||
G1 | 60 (100%) | 34 (56.7%) | 20 (33.3%) | 6 (10%) | |
G2 | 92 (100%) | 39 (42.4%) | 32 (34.8%) | 21 (22.8%) | |
G3 | 55 (100%) | 17 (30.9%) | 14 (25.5%) | 24 (43.6%) | |
Nodal status | 0.04* | ||||
negative | 130 (100%) | 66 (50.8%) | 36 (27.7%) | 28 (21.5%) | |
positive | 70 (100%) | 23 (32.9%) | 28 (40%) | 19 (27.1%) | |
pT-Stage | 0.43 | ||||
pT1 | 117 (100%) | 52 (44.4%) | 41 (35%) | 24 (20.6%) | |
pT2/pT3 | 79 (100%) | 32 (40.5%) | 22 (27.9%) | 25 (31.6%) | |
pT4 | 10 (100%) | 5 (50%) | 3 (30%) | 2 (20%) | |
Hormone receptor status | 0.02* | ||||
Hormone receptor positive | 163 (100%) | 73 (44.8%) | 59 (36.2%) | 31 (19%) | |
Hormone receptor negative | 43 (100%) | 17 (39.5%) | 7 (16.3%) | 19 (44.2%) | |
HER2 status | 0.005* | ||||
negative | 178 (100%) | 83 (46.6%) | 55 (30.9%) | 40 (22.5%) | |
positive | 25 (100%) | 5 (20%) | 9 (36%) | 11 (44%) |